The Combination of NPM1, DNMT3A and IDH1/2 Mutations Leads to Inferior Overall Survival in AML

American Journal of Hematology - United States
doi 10.1002/ajh.25517
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

A Distinct Immunophenotype Identifies a Subset of NPM1 -Mutated AML With TET2 or IDH1/2 Mutations and Improved Outcome

American Journal of Hematology
Hematology
2018English

IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma

Journal of Cancer
Oncology
2018English

Dominating the Negative: How DNMT3A Mutations Contribute to AML Pathogenesis

Cell Stem Cell
Molecular MedicineGeneticsCell Biology
2017English

Biological and Clinical Influences of NPM1 in Acute Myeloid Leukemia Patients With DNMT3A Mutations

Cancer Management and Research
Oncology
2018English

Impact of Chemotherapy Delay on Overall Survival for AML With I DH1/2 Mutations: A Study in Adult Chinese Patients

Blood
BiochemistryImmunologyCell BiologyHematology
2015English

SRSF2 Mutations in Primary Myelofibrosis: Significant Clustering With IDH Mutations and Independent Association With Inferior Overall and Leukemia-Free Survival

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Mutations of the Epigenetics-Modifying Gene (DNMT3a, TET2, IDH1/2) at Diagnosis May Induce FLT3-ITD at Relapse in De Novo Acute Myeloid Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2012English

Cancer-Associated IDH1 Mutations Produce 2-Hydroxyglutarate

Nature
Multidisciplinary
2009English

Prognostic Relevance of DNMT3A R882 Mutations in AML Patients Undergoing Non-Myeloablative Conditioning Hematopoietic Stem Cell Transplantation

Bone Marrow Transplantation
TransplantationHematology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy